Literature DB >> 33022115

Antidepressant Medications and Weight Change: A Narrative Review.

Hartej Gill1,2, Barjot Gill1, Sabine El-Halabi1, David Chen-Li1, Orly Lipsitz1, Joshua Daniel Rosenblat1,3,4, Tamsyn E Van Rheenen5,6, Nelson B Rodrigues1, Rodrigo B Mansur1,3, Amna Majeed1, Leanna M W Lui1, Flora Nasri1, Yena Lee1,2, Roger S Mcintyre1,2,3,4,7.   

Abstract

Antidepressant medications are the first-line treatment option for moderate to severe major depressive disorder. However, most antidepressants have numerous documented adverse events, including cardiometabolic effects and weight gain, which are major public health concerns. Antidepressant agents provide varying risk of associated weight gain, including significant within-class differences. Some agents, such as mirtazapine, show significant levels of weight gain, while others, such as bupropion, demonstrate weight-loss effects. Current findings suggest the role of histamine and serotonin off-target appetite-promoting pathways in adverse weight-gain effects. Therefore, controlling for undesired weight effects is an important consideration for the selection of antidepressants.
© 2020 The Obesity Society.

Entities:  

Year:  2020        PMID: 33022115     DOI: 10.1002/oby.22969

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  6 in total

1.  The Effect of Bariatric Surgery on Long-term Depression Treatment in Patients With Obesity.

Authors:  Valerie A Smith; Matthew L Maciejewski; Theodore S Z Berkowitz; James E Mitchell; Chuan-Fen Liu; Katharine A Bradley; Maren K Olsen; Edward L Livingston; David E Arterburn
Journal:  Ann Surg       Date:  2022-07-06       Impact factor: 13.787

Review 2.  Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.

Authors:  Mark J Millan
Journal:  Ther Adv Psychopharmacol       Date:  2022-06-30

3.  Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study.

Authors:  Beini Lyu; Alex R Chang; Lesley A Inker; Elizabeth Selvin; Morgan E Grams; Jung-Im Shin
Journal:  Lancet Reg Health Am       Date:  2022-04-02

4.  Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.

Authors:  Maria L Ricardo-Silgado; Sneha Singh; Lizeth Cifuentes; Paul A Decker; Daniel Gonzalez-Izundegui; Ann M Moyer; Maria D Hurtado; Michael Camilleri; Suzette J Bielinski; Andres Acosta
Journal:  BMC Med       Date:  2022-07-26       Impact factor: 11.150

5.  Effect of Epigallocatechin-3-gallate on Stress-Induced Depression in a Mouse Model: Role of Interleukin-1β and Brain-Derived Neurotrophic Factor.

Authors:  Nabila E Abdelmeguid; Tasneem M Hammad; Ashraf M Abdel-Moneim; Sherine Abdel Salam
Journal:  Neurochem Res       Date:  2022-08-08       Impact factor: 4.414

Review 6.  Melanocortin Signaling Connecting Systemic Metabolism With Mood Disorders.

Authors:  Francesca Copperi; Jung Dae Kim; Sabrina Diano
Journal:  Biol Psychiatry       Date:  2021-06-05       Impact factor: 12.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.